Life Sciences Equipment & Services / Genomics Technology
Strategic Profile
The company is expanding impact of its platforms, driven by new product innovations and strategic partnerships, well positioned to execute across multiple growth vectors in the business, especially AI-driven demand, translational research and emerging clinical opportunities. The company maintains a robust gross margin of 68.84%, indicating efficient production processes.
Cyborg Score Rationale
The company faces challenges in profitability, with a negative operating margin of -22% and a net margin of -11.89%. However, 10x Genomics exhibits strong financial health with a current ratio of 4.48 and a quick ratio of 4.06, reflecting ample liquidity, and maintains a low debt-to-equity ratio of 0.11, underscoring a conservative capital structure.
Top Insights
Strong adoption rates of new technologies, such as Flex V2, are bolstering the company's position in the competitive genomics sector.
Multiple strategic partnerships launched including PharosAI cancer dataset collaboration, Brigham & Women's Hospital autoimmune disease study, and Dana-Farber multi-year tumor analysis collaboration.
Consumables revenue grew to approximately $507.2M for the year, up 3% YoY, indicating recurring revenue strength.
The firm maintains a robust current ratio of 4.5 with a substantial cash position of $473.97 million, providing financial flexibility.
Named Competitors
SMRT Sequencing — Long-read DNA sequencing technology